# US 2023/0277445 A1 · Adhesive drug carrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0277445 A1
- Document ID: US20230277445A1
- Status: Published application
- Kind: A1
- Application number: 18/001,375
- Filed: 2021-06-10
- Published: 2023-09-07
- Earliest claimed: 2020-06-11
- Assignees: UMC Utrecht Holding B.V.; SentryX B.V.
- Applicants: UMC Utrecht Holding B.V.; SentryX B.V.
- Inventors: Susanna Piluso; Jasper Gerard Steverink; Floris Rudolf Van Tol; Raymond Michel Schiffelers; Bas Jeroen Oosterman; Joannes Jacobus Verlaan
- Web page: https://patentgrep.com/patent/US20230277445A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61L 24/0015: {Medicaments; Biocides}
- A61L 24/0031: {Hydrogels or hydrocolloids}
- A61L 24/104: {Gelatin}
- A61L 2300/402: Anaestetics, analgesics, e.g. lidocaine
- A61L 2300/418: Agents promoting blood coagulation, blood-clotting agents, embolising agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The present invention relates to an adhesive drug carrier comprising an injectable hydrogel comprising at least one medication, wherein the hydrogel comprises a (i) a protein-based polymer functionalized with a functionalization agent that is able to form guest-host interactions with oxidized P-cyclodextrin, cross-linked with (ii) an oxidized P-cyclodextrin (oβ-CD) as matrix and the at least one medication (iii), and wherein the hydrogel further comprises (iv) a protein-based polymer bearing quinone and/or catechol groups. The invention further relates to a method for its preparation and a method for treatment.

## Claims

### Claim 1

An adhesive drug carrier comprising an injectable hydrogel comprising at least one medication, wherein the hydrogel comprises (i) a protein-based polymer functionalized with a functionalization agent that is able to form guest-host interactions with oxidized β-cyclodextrin, cross-linked with (ii) an oxidized β-cyclodextrin (oβ-CD) as matrix and the at least one medication (iii), and wherein the hydrogel further comprises (iv) a protein-based polymer bearing quinone and/or catechol groups, wherein
the protein-based polymer (iv) has a molecular weight in the range of 50 to 200 kDa and bears from 15% to 70% of the total amino groups of combined catechol and/or quinone groups per molecule;
the protein-base polymer (i) and the protein-based polymer (iv) are selected from silk, fibrin, collagen or gelatin;
the amount of oβ-CD is from 0.1 to 10% by weight of the hydrogel, and
the at least one medication (iii) is a small drug molecule with a molecular weight of less than 1000 Daltons.

### Claim 2 (depends on 1)

The adhesive drug carrier according to claim 1, wherein the hydrogel comprises (iv) a protein-based polymer bearing quinone groups and a protein-based polymer bearing catechol groups.

### Claim 3 (depends on 2)

The adhesive drug carrier according to claim 2, wherein the hydrogel comprises a cross-linked mixture of (i), (iv) and (ii), with (i) and (iv) in a weight ratio selected from a group consisting of: 9:1 to 1:9, 7:3 to 3:7, 3:2 to 2:3, about 1: 1.

### Claim 4 (depends on 1)

The adhesive drug carrier according to claim 1, wherein the protein-based polymer (i) and the protein based polymer (iv) are the same.

### Claim 5 (depends on 1)

The adhesive drug carrier according to claim 1, wherein the protein-based polymer (i) is functionalized with a primary aminoalkylphenol or with a hydroxyphenyl propionic acid.

### Claim 6 (depends on 1)

The adhesive drug carrier according to claim 1, wherein the protein-based polymer (iv) is made by modification with 2-(3,4-dihydroxyphenyl)ethylamine hydrochloride (dopamine), 3,4-dihydroxy-L-phenylalanine (DOPA), 3-(3,4-dihydroxyphenyl)-2-propenoic acid (CA, caffeic acid), 3-(3,4-dihydroxyphenyl)propanoic acid (DHC, dihydrocaffeic acid), 3,4,5-trihydroxybenzoic acid (gallic acid), (R)-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-benzenediol (epinephrine), or (R)-4-(2-amino-1-hydroxyethyl)-1,2-benzeendiol (norepinephrine).

### Claim 7 (depends on 1)

The adhesive drug carrier according to claim 1, wherein the medication (iii) is selected from the group including: a hydrophobic medication, a pain-relieving medicament, a local anesthetic, and bupivacaine.

### Claim 8 (depends on 1)

The adhesive drug carrier according to claim 1, for use in the treatment of medical disorders, wherein the hydrogel is adhered to itself, bone, tissue or surgical metal by way of the protein-based polymer bearing quinone and/or catechol groups.

### Claim 9 (depends on 1)

The adhesive drug carrier according to claim 1, for use as hemostatic or for the delivery of antigens, nucleic acids-encoding agents or antigen-encoding viral vectors, wherein the hydrogel is adhered to itself, bone, tissue or surgical metal by way of the protein-based polymer bearing quinone and/or catechol groups.

### Claim 10 (depends on 1)

The adhesive drug carrier according to claim 1, as a kit of parts.

### Claim 11 (depends on 1)

A method for preparing the adhesive drug carrier according to claim 1, wherein (iv) is part of the cross-linked hydrogel, the method comprising:
preparing a mixed solution of (i) the protein-based polymer functionalized with functionalization agent, (ii) oβ-CD, (iii) the medication, (iv), the protein-based polymer bearing quinone and/or catechol groups, and
crosslinking the hydrogel.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the mixed solution of (i), (ii), (iii) and (iv) is introduced by injection into or applied onto a patient prior to crosslinking.

### Claim 13 (depends on 1)

A method for treatment of medical disorders, comprising the localized application of the adhesive drug carrier according to claim 1.

### Claim 14 (depends on 1)

A method for use as hemostatic or for the delivery of antigens or antigen-coding viral vectors, comprising the localized application of the adhesive drug carrier according to claim 1.

### Claim 15 (depends on 4)

The adhesive drug carrier according to claim 4, wherein the protein-based polymer (i) and the protein based polymer (iv) are the same, being gelatin.

### Claim 16 (depends on 5)

The adhesive drug carrier according to claim 5, wherein the protein-based polymer (i) is functionalized with tyramine or with 3-(4-hydroxyphenyl)propionic acid.

### Claim 17 (depends on 5)

The adhesive drug carrier according to claim 5, wherein the protein-based polymer (i) is gelatin functionalized with tyramine (GTA) or gelatin functionalized with desaminotyrosine.

### Claim 18 (depends on 1)

The adhesive drug carrier according to claim 1, for use in the treatment of a disorder selected from the group including: musculoskeletal disorders, infection, inflammation, auto-immune disease, malignant and benign neoplasms, growth disorders, trauma and degenerative disorders, or treatment of pain arising from surgical treatment of these disorders, wherein the hydrogel is adhered to itself, bone, tissue or surgical metal by way of the protein-based polymer bearing quinone and/or catechol groups.

### Claim 19 (depends on 10)

The adhesive drug carrier according claim 10, as a kit of parts, for use in a dual barrel syringe.

### Claim 20 (depends on 1)

A method for treatment of a disorder selected from the group including: musculoskeletal disorders, infection, inflammation, auto-immune disease, malignant and benign neoplasms, growth disorders, trauma and degenerative disorders, or treatment of pain arising from surgical treatment of these disorders, comprising the localized application of the adhesive drug carrier according to claim 1.
